11	27	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Introduction'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 15), 'text':'The identification of distinct subgroups of breast cancer has led to the development of therapeutic strategies'}, {'start':(1, 16), 'end':(1, 24), 'text':'that exploit the underlying biology of the subtype ,'}]}, {'start':(1, 25), 'end':(1, 43), 'text':'with hormonal therapies and HER2 targeting agents for hormone receptor positive and HER2 positive breast cancers , respectively .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 48), 'text':'Tumours lacking expression of hormone receptors ( oestrogen receptor ( ER ) and progesterone receptor ( PR ) ) and HER2 ( triple negative breast cancers , TNBCs ) , on the other hand , pose a significant clinical challenge due to a poor understanding of the genetic alternations'}, {'start':(2, 49), 'end':(2, 54), 'text':'that underlie the development of TNBC'}]}, {'start':(2, 55), 'end':(2, 67), 'text':'and this is reflected in a lack of subtype specific targeted therapies .'}]}, {'start':(3, 0), 'end':(3, 18), 'text':'TNBCs comprise a heterogeneous group of breast cancers and account for 10-15 % of all invasive breast cancers .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 15), 'text':'Histologically , the majority of TNBCs are grade III invasive ductal carcinomas of no special type'}, {'start':(4, 16), 'end':(4, 19), 'text':'( IDC-NST ) ,'}]}, {'start':(4, 20), 'end':(4, 39), 'text':'although the majority of medullary , metaplastic and adenoid cystic carcinomas also display a triple negative phenotype ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 7), 'text':'These tumours are more prevalent in young women'}, {'start':(5, 8), 'end':(5, 21), 'text':'( < 50 years ) and in women of African and Hispanic descent .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'cause', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 4), 'text':'TNBCs have a poor prognosis'}, {'start':(6, 5), 'end':(6, 9), 'text':'characterised by early relapse ,'}]}, {'start':(6, 10), 'end':(6, 18), 'text':'potentially reflecting the high proliferative rate of TNBCs .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 9), 'text':'Similarly , women with TNBCs have a significantly shorter survival'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(7, 10), 'end':(7, 11), 'text':'following recurrence'}, {'start':(7, 12), 'end':(7, 21), 'text':'when compared to those with non triple negative cancers .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'condition', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 11), 'text':'Therefore , the identification of novel therapeutic targets for TNBCs is important'}, {'start':(8, 12), 'end':(8, 24), 'text':'if the outcome of patients with these tumours is to be improved .'}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 7), 'text':'Based on the concept of oncogene addiction ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(9, 8), 'end':(9, 12), 'text':'we and others have demonstrated'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 13), 'end':(9, 14), 'text':'that genes'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(9, 15), 'end':(9, 18), 'text':'that are consistently overexpressed'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 19), 'end':(9, 30), 'text':'when amplified may be selectively required for the survival of cancer cells'}, {'start':(9, 31), 'end':(9, 34), 'text':'harbouring their amplification ,'}]}, {'start':(9, 35), 'end':(9, 43), 'text':'and can be exploited as potential therapeutic targets .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 9), 'text':'Previous studies have examined TNBCs with expression profiling and microarray'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 10), 'end':(10, 13), 'text':'based comparative genomic hybridisation'}, {'start':(10, 14), 'end':(10, 17), 'text':'( aCGH ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 8), 'text':'These studies have found TNBCs to be heterogeneous ,'}, {'start':(11, 9), 'end':(11, 16), 'text':'with complex genomic profiles and infrequent amplifications .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 5), 'text':'To identify amplicon drivers and genes'}, {'start':(12, 6), 'end':(12, 16), 'text':'that have the potential to be therapeutic targets in TNBCs ,'}]}, {'start':(12, 17), 'end':(12, 30), 'text':'we integrated aCGH and gene expression data from a large series of TNBCs .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(13, 0), 'end':(13, 11), 'text':'Our aims were to characterise the genomic and transcriptomic profiles of TNBCs'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 12), 'end':(13, 16), 'text':'and identify and validate genes'}, {'label':'joint', 'direction':'None', 'children':[{'start':(13, 17), 'end':(13, 20), 'text':'that are recurrently amplified'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(13, 21), 'end':(13, 23), 'text':'and consistently overexpressed'}, {'start':(13, 24), 'end':(13, 28), 'text':'when amplified in TNBCs .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(14, 0), 'end':(14, 14), 'text':'We found more frequent high level , focal amplifications than previously described ( ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 15), 'end':(14, 19), 'text':'and identified potential therapeutic targets'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(14, 20), 'end':(14, 23), 'text':'that are consistently overexpressed'}, {'start':(14, 24), 'end':(14, 26), 'text':'when amplified .'}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(15, 0), 'end':(15, 16), 'text':'We validated the fibroblast growth factor receptor 2 ( FGFR2 ) gene as one of these targets'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(15, 17), 'end':(15, 20), 'text':'and provided functional data'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(15, 21), 'end':(15, 22), 'text':'to suggest'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 23), 'end':(15, 38), 'text':'that this tyrosine kinase receptor may be a novel therapeutic target in a subset of TNBCs'}, {'start':(15, 39), 'end':(15, 43), 'text':'harbouring FGFR2 gene amplification .'}]}]}]}]}]}]}]}
0	1	{'start':(0, 0), 'end':(0, 14), 'text':'Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets'}
202	203	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 4'}
195	196	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 8'}
192	193	{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Material'}
200	201	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 2'}
1	11	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(0, 0), 'end':(0, 11), 'text':'Triple negative breast cancers ( TNBCs ) have a relatively poor prognosis'}, {'start':(0, 12), 'end':(0, 22), 'text':'and can not be effectively treated with current targeted therapies .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 3), 'text':'We searched for genes'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(1, 4), 'end':(1, 11), 'text':'that have the potential to be therapeutic targets'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(1, 12), 'end':(1, 13), 'text':'by identifying'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(1, 14), 'end':(1, 16), 'text':'genes consistently over-expressed'}, {'start':(1, 17), 'end':(1, 19), 'text':'when amplified .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 10), 'text':'Fifty-six TNBCs were subjected to high-resolution microarray based comparative genomic hybridisation'}, {'start':(2, 11), 'end':(2, 14), 'text':'( aCGH ) ,'}]}, {'start':(2, 15), 'end':(2, 25), 'text':'of which 24 were subjected to genome-wide gene expression analysis .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 4), 'text':'TNBCs were genetically heterogeneous ;'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 5), 'end':(3, 14), 'text':'no individual focal amplification was present at high frequency ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 15), 'end':(3, 19), 'text':'although 78.6 % of TNBCs'}, {'start':(3, 20), 'end':(3, 26), 'text':'harboured at least one focal amplification .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 8), 'text':'Integration of aCGH and expression data revealed 40 genes'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(4, 9), 'end':(4, 10), 'text':'significantly overexpressed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 11), 'end':(4, 13), 'text':'when amplified ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(4, 14), 'end':(4, 45), 'text':'including the known oncogenes and potential therapeutic targets , FGFR2 ( 10q26 .3 ) , BUB3 ( 10q26 .3 ) , RAB20 ( 13q34 ) , PKN1 ( 19p13 .12 ) ,'}, {'start':(4, 46), 'end':(4, 52), 'text':'and NOTCH3 ( 19p13 .12 ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(5, 0), 'end':(5, 9), 'text':'We identified two TNBC cell lines with FGFR2 amplification ,'}, {'start':(5, 10), 'end':(5, 17), 'text':'which both had constitutive activation of FGFR2 .'}]}]}, {'start':(6, 0), 'end':(6, 17), 'text':'Amplified cell lines were highly sensitive to FGFR inhibitor PD173074 , and to RNAi silencing of FGFR2 .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 4), 'text':'Treatment with PD173074 induced apoptosis'}, {'start':(7, 5), 'end':(7, 12), 'text':'resulting partly from inhibition of PI3K-AKT signalling .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 1), 'text':'Independent validation'}, {'start':(8, 2), 'end':(8, 7), 'text':'using publicly available aCGH datasets revealed'}]}, {'label':'contrast', 'direction':'None', 'children':[{'start':(8, 8), 'end':(8, 22), 'text':'FGFR2 gene was amplified in 4 % ( 6 and 165 ) of TNBC ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 23), 'end':(8, 27), 'text':'but not in other subtypes'}, {'start':(8, 28), 'end':(8, 37), 'text':'( 0 and 214 , p = 0.0065 ) .'}]}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 2), 'text':'Our analysis demonstrates'}, {'start':(9, 3), 'end':(9, 17), 'text':'that TNBCs are heterogeneous tumours with amplifications of FGFR2 in a subgroup of tumours .'}]}]}
92	162	{'label':'topic-change', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Results'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 4), 'text':'TNBCs display complex genomic profiles'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 0), 'end':(2, 17), 'text':'We established the genomic array CGH profiles of 56 TNBCs with an array CGH platform with a previously'}, {'start':(2, 18), 'end':(2, 23), 'text':'validated effective resolution of 50Kb .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 12), 'text':'This revealed a high level of genetic instability , with gain or loss'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 13), 'end':(3, 21), 'text':'affecting a median of 44.4 % of the genome'}, {'start':(3, 22), 'end':(3, 29), 'text':'( range 9.3 % -76.7 % ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 0), 'end':(4, 4), 'text':'Using the genomic pattern classification'}, {'label':'joint', 'direction':'None', 'children':[{'start':(4, 5), 'end':(4, 20), 'text':'proposed by 15 of the TNBCs ( 27 % ) were classified as \' simplex \''}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 21), 'end':(4, 36), 'text':'and 41 ( 73 % ) were considered to have \' complex \' genomic patterns ,'}, {'start':(4, 37), 'end':(4, 60), 'text':'of which 28 ( 50 % ) were \' sawtooth \' and 13 ( 23 % ) were \' firestorm \' ( ) .'}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 15), 'text':'Given that the majority of TNBCs displayed \' sawtooth \' patterns , it is not surprising'}, {'start':(5, 16), 'end':(5, 26), 'text':'that multiple regions of recurrent gains and losses were identified .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 40), 'text':'In agreement with previous studies , loss of 1p36-p34 , 5q11-q35 , 8p23.3-p12 and 17p13-q21 and gain of 3q22-q26 , 6p25-p21 , 7q32-q36 , 8p11-q24 , 10p15.3-p11 .21 and 12p13-p11 were found in > 30 % of TNBCs ( ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 10), 'text':'Recurrent high level gains and amplifications were found in TNBCs .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(8, 0), 'end':(8, 8), 'text':'At least one focal amplification ( < 10Mb )'}, {'start':(8, 9), 'end':(8, 23), 'text':'was found in 78.6 % ( 44 and 56 ) of cases ; however ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 24), 'end':(8, 32), 'text':'the prevalence of each amplification was relatively low ,'}, {'start':(8, 33), 'end':(8, 42), 'text':'ranging from 4 % to 27 % ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 0), 'end':(9, 8), 'text':'Integrative aCGH and expression analysis reveal pathways and networks'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 9), 'end':(9, 13), 'text':'that are enriched for genes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 14), 'end':(9, 19), 'text':'whose expression correlates with copy number'}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 3), 'text':'To determine the genes'}, {'start':(10, 4), 'end':(10, 11), 'text':'whose expression levels correlate with copy number ,'}]}, {'start':(10, 12), 'end':(10, 26), 'text':'we overlaid aCGH and expression data in an unbiased , genome-wide fashion ( ) .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(11, 0), 'end':(11, 2), 'text':'This analysis revealed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 3), 'end':(11, 24), 'text':'that the expression of 4972 out of 24565 genes ( 20.2 % ) correlated with copy number changes ( Pearson \'s correlation'}, {'start':(11, 25), 'end':(11, 31), 'text':'adjusted p < 0.05 , ) .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(12, 0), 'end':(12, 2), 'text':'This analysis suggests'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 3), 'end':(12, 9), 'text':'that a large proportion of the genes'}, {'start':(12, 10), 'end':(12, 23), 'text':'expressed in TNBCs are at least in part regulated by copy number changes .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 6), 'text':'Within this list we determined the genes'}, {'start':(13, 7), 'end':(13, 33), 'text':'whose expression was significantly upregulated or downregulated in the presence of copy number gain or loss respectively ( Mann-Whitney U adjusted p < 0.05 , ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 3), 'text':'We identified 324 genes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 4), 'end':(14, 12), 'text':'whose mRNA expression levels were significantly higher in tumours'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 13), 'end':(14, 20), 'text':'harbouring DNA copy number gains and 39 genes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 21), 'end':(14, 29), 'text':'whose mRNA expression levels were significantly lower in tumours'}, {'start':(14, 30), 'end':(14, 35), 'text':'displaying DNA copy number loss .'}]}]}]}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 0), 'end':(15, 4), 'text':'The lower number of genes'}, {'start':(15, 5), 'end':(15, 6), 'text':'down regulated'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(15, 7), 'end':(15, 18), 'text':'when lost may stem from the slightly lower sensitivity of array CGH'}, {'start':(15, 19), 'end':(15, 36), 'text':'to detect loss of a single copy of a genomic region in highly aneuploid tumours ( ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(15, 37), 'end':(15, 50), 'text':'coupled with the limitations of expression arrays to accurately determine the expression of genes'}, {'start':(15, 51), 'end':(15, 55), 'text':'expressed at low levels .'}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 7), 'text':'Ingenuity pathway analysis ( IPA ) of genes'}, {'start':(16, 8), 'end':(16, 11), 'text':'expressed at higher levels'}]}, {'start':(16, 12), 'end':(16, 14), 'text':'when gained revealed'}]}, {'start':(16, 15), 'end':(16, 24), 'text':'that 5 networks and 27 canonical pathways were significantly enriched'}]}, {'start':(16, 25), 'end':(16, 27), 'text':'( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 7), 'text':'Importantly , the canonical pathways of growth factors'}, {'start':(17, 8), 'end':(17, 11), 'text':'that have been shown'}]}, {'start':(17, 12), 'end':(17, 29), 'text':'to play a role in breast cancer development and progression , or to be potential therapeutic targets ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 30), 'end':(17, 34), 'text':'were significantly enriched with genes'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(17, 35), 'end':(17, 35), 'text':'upregulated'}, {'start':(17, 36), 'end':(17, 40), 'text':'when gained ( ) .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(18, 0), 'end':(18, 10), 'text':'Copy number gains of the tyrosine kinase receptors were rare ,'}, {'start':(18, 11), 'end':(18, 35), 'text':'and the growth factor pathway enrichment reflected frequent copy number gains and over-expression of key adapter molecules and down-stream signal transduction kinases ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 7), 'text':'The p53 signalling pathway was enriched for genes'}, {'start':(19, 8), 'end':(19, 10), 'text':'that are upregulated'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 11), 'end':(19, 13), 'text':'when gained ,'}, {'start':(19, 14), 'end':(19, 19), 'text':'including survivin ( BIRC5 ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 6), 'text':'Recurrent amplified regions and potential amplicon drivers'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 4), 'text':'We next analysed the data'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 5), 'end':(21, 8), 'text':'to identify the genes'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(21, 9), 'end':(21, 12), 'text':'that were significantly overexpressed'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(21, 13), 'end':(21, 17), 'text':'when amplified in TNBCs ,'}, {'start':(21, 18), 'end':(21, 23), 'text':'compared to non amplified cancers .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 5), 'text':'This analysis revealed only 40 genes'}, {'start':(22, 6), 'end':(22, 9), 'text':'( Mann-Whitney U test'}]}, {'start':(22, 10), 'end':(22, 15), 'text':'adjusted p < 0.05 , )'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 16), 'end':(22, 19), 'text':'but included multiple genes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 20), 'end':(22, 38), 'text':'that have been shown to either have oncogenic properties or to be potential therapeutic targets , such as FGFR2'}, {'start':(22, 39), 'end':(22, 62), 'text':'( 10q26 ) , BUB3 ( 10q26 ) , RAB20 ( 13q34 ) , NOTCH3 ( 19p13 ) and PKN1 ( 19p13 ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(23, 0), 'end':(23, 3), 'text':'It should be noted'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 4), 'end':(23, 14), 'text':'that this analysis , with a non parametric rank sum test'}, {'start':(23, 15), 'end':(23, 22), 'text':'corrected for false discovery , is intentionally conservative'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 23), 'end':(23, 26), 'text':'and will identify genes'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(23, 27), 'end':(23, 30), 'text':'that are robustly over-expressed'}, {'start':(23, 31), 'end':(23, 33), 'text':'when amplified .'}]}]}]}]}, {'start':(24, 0), 'end':(24, 9), 'text':'Such an analysis is not intended to be exhaustive .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 9), 'text':'Of the 40 genes , 38 also displayed expression levels'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 10), 'end':(25, 14), 'text':'that correlated with copy number'}, {'start':(25, 15), 'end':(25, 22), 'text':'as assessed by Pearson correlation ( ) .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 0), 'text':'Genes'}, {'start':(26, 1), 'end':(26, 4), 'text':'that are robustly over-expressed'}]}, {'start':(26, 5), 'end':(26, 26), 'text':'when amplified potential amplicon driver , and therapeutic targets , as has been suggested for NOTCH3 ( ) , and BUB3 .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 12), 'text':'FGFR2 is amplified in triple negative breast cancers and breast cancer cell lines'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(28, 0), 'end':(28, 2), 'text':'We selected ,'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(28, 3), 'end':(28, 15), 'text':'for further investigation , FGFR2 amplifications from the list amplified and over-expressed ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 16), 'end':(28, 27), 'text':'as there are a number of drugs in early phase clinical trials'}, {'start':(28, 28), 'end':(28, 32), 'text':'that target the FGFRs .'}]}]}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 9), 'text':'A re-analysis of data from publicly available aCGH datasets ,'}, {'start':(29, 10), 'end':(29, 15), 'text':'including our current data set ,'}]}, {'start':(29, 16), 'end':(29, 53), 'text':'revealed FGFR2 amplification in 4 % ( 6 and 165 95 % CI 1.4-7 .8 % ) of TNBCs , with no cases of FGFR2 amplification in other subtypes ( 0 and 214 , p = 0.0065 .'}]}]}, {'start':(30, 0), 'end':(30, 5), 'text':'Fisher \'s exact test ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(31, 0), 'end':(31, 4), 'text':'Excluding our data set ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(31, 5), 'end':(31, 28), 'text':'the frequency was similar ( TNBC 4 % ( 4 and 109 ) vs other subtypes 0 % ( 0 and 214 ) ,'}, {'start':(31, 29), 'end':(31, 33), 'text':'p = 0.0125 ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(32, 0), 'end':(32, 9), 'text':'We screened a panel of 51 breast cancer cell lines'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(32, 10), 'end':(32, 20), 'text':'using a combination of aCGH and western blotting of cell lysates'}, {'start':(32, 21), 'end':(32, 32), 'text':'to identify cell lines with FGFR2 gene amplification and protein overexpression .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(33, 0), 'end':(33, 7), 'text':'We identified two cell lines with FGFR2 amplification'}, {'start':(33, 8), 'end':(33, 20), 'text':'one of which , SUM52PE , had been described previously ( ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(34, 0), 'end':(34, 11), 'text':'MFM223 was found to express high levels of FGFR2 protein ( )'}, {'start':(34, 12), 'end':(34, 22), 'text':'and to harbour FGFR2 gene amplification by aCGH ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(35, 0), 'end':(35, 8), 'text':'FGFR2 amplification was confirmed by FGFR2 FISH in MFM223'}, {'start':(35, 9), 'end':(35, 11), 'text':'( ) ,'}]}, {'start':(35, 12), 'end':(35, 19), 'text':'and by copy number PCR ( ) .'}]}, {'start':(36, 0), 'end':(36, 32), 'text':'Both amplified cell lines expressed substantially higher FGFR2 mRNA than all other cell lines ( SUM52PE 67 fold and MFM223 26 fold higher than median expression of non amplified lines , ) .'}]}]}]}, {'start':(37, 0), 'end':(37, 29), 'text':'Both MFM223 and SUM52 were found to be triple negative , with neither cell line expressing ER or PR by western blotting nor harbouring HER2 gene amplification ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(38, 0), 'end':(38, 17), 'text':'FGFR2 expression and tyrosine kinase activity are required for the survival of cell lines with FGFR2 gene amplification'}, {'start':(39, 0), 'end':(39, 12), 'text':'We transfected a panel of cell lines with FGFR2 siRNA ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(40, 0), 'end':(40, 9), 'text':'FGFR2 silencing selectively reduced the survival of MFM223 cells ,'}, {'label':'comparison', 'direction':'LeftToRight', 'children':[{'start':(40, 10), 'end':(40, 14), 'text':'FGFR2 amplified cell line ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 15), 'end':(40, 19), 'text':'compared to all transfectable non'}, {'start':(40, 20), 'end':(40, 23), 'text':'amplified cell lines .'}]}]}]}, {'start':(41, 0), 'end':(41, 12), 'text':'Silencing of FGFR2 by siRNA has confirmed by western blot ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(42, 0), 'end':(42, 23), 'text':'We then examined the sensitivity of the cell line panel to PD173074 , a highly potent selective pan-FGFR tyrosine kinase inhibitor ( ) .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 18), 'text':'The FGFR2 amplified cell lines were substantially more sensitive to PD173074 than all comparator cell lines ( ) ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(43, 19), 'end':(43, 19), 'text':'indicating'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 20), 'end':(43, 34), 'text':'that FGFR kinase activity was selectively required for the growth and survival of cell lines'}, {'start':(43, 35), 'end':(43, 39), 'text':'harbouring FGFR2 gene amplification .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(44, 0), 'end':(44, 7), 'text':'Ligand independent signalling in FGFR2 amplified cell lines'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 22), 'text':'Signalling through the FGFR family of growth receptors is reliant on the adapter protein Fibroblast Receptor Substrate 2 alpha ( FRS2 ) ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 23), 'end':(45, 28), 'text':'which binds directly to phosphorylated FGFR'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 29), 'end':(45, 32), 'text':'forming a FRS2-SOS-GRB2 complex'}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(45, 33), 'end':(45, 40), 'text':'to activate MAPK signalling and a FRS2-SOS-GAB1 complex'}, {'start':(45, 41), 'end':(45, 45), 'text':'to activate PI3K-AKT signalling .'}]}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(46, 0), 'end':(46, 1), 'text':'We examined'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 2), 'end':(46, 5), 'text':'the signal transduction pathways'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 6), 'end':(46, 17), 'text':'activated downstream of FGFR2 in serum starved conditions with and without PD173074'}, {'start':(46, 18), 'end':(46, 23), 'text':'to inhibit FGFR2 kinase activity .'}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 0), 'end':(47, 5), 'text':'FRS2 exhibits a mobility shift ,'}, {'start':(47, 6), 'end':(47, 8), 'text':'reflecting phosphorylation ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 9), 'end':(47, 15), 'text':'in serum starved amplified cell lines ,'}, {'start':(47, 16), 'end':(47, 23), 'text':'which is abolished by treatment with PD173074 ,'}]}, {'start':(47, 24), 'end':(47, 34), 'text':'indicating ligand independent constitutive activation of the receptor ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(48, 0), 'end':(48, 8), 'text':'In both cell lines harbouring FGFR2 gene amplification ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(48, 9), 'end':(48, 26), 'text':'AKT Ser473 was phosphorylated in an FGFR kinase dependent manner , with ERK1 and 2 Thr202 and Tyr204'}, {'start':(48, 27), 'end':(48, 36), 'text':'phosphorylated in an FGFR kinase dependent fashion in MFM223 .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 0), 'end':(49, 7), 'text':'SUM52PE expressed low levels of phosphorylated ERK ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 8), 'end':(49, 20), 'text':'which presumably was reflected in the low proliferative rate of this cell line'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 21), 'end':(49, 22), 'text':'( data'}, {'start':(49, 23), 'end':(49, 26), 'text':'not shown ) .'}]}]}]}, {'start':(50, 0), 'end':(50, 24), 'text':'Phosphorylation of AKT and ERK1 and 2 was independent of FGFR kinase activity in control cell lines MCF7 , SKBR3 and HCC1143 ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 0), 'end':(51, 5), 'text':'FGFR2 amplified MFM223 die by apoptosis'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 6), 'end':(51, 8), 'text':'following FGFR inhibition'}, {'start':(52, 0), 'end':(52, 13), 'text':'We investigated the mechanism of loss of survival in MFM223 on PD173074 treatment .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'contrast', 'direction':'RightToLeft', 'children':[{'start':(53, 0), 'end':(53, 22), 'text':'After 48 hr treatment with PD173074 there was no significant alteration of the cell cycle profile of the MCF7 control cell line ,'}, {'start':(53, 23), 'end':(53, 36), 'text':'but there was a substantial increase in subG1 cells in MFM223 ( ) .'}]}, {'label':'evaluation', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(54, 0), 'end':(54, 10), 'text':'To investigate whether the increase in subG1 reflected increased apoptosis ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 11), 'end':(54, 22), 'text':'we assessed Annexin V and PI staining in MCF7 and MFM223 cells'}, {'start':(54, 23), 'end':(54, 30), 'text':'treated for 48hrs with PD173074 ( ) .'}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'start':(55, 0), 'end':(55, 35), 'text':'There was no difference in the proportion of apoptotic , Annexin V positive and PI negative , cells in MCF7 without and with PD173074 ( 4.8 % vs 3.5 % , p = NS ) ,'}, {'start':(55, 36), 'end':(55, 57), 'text':'but a substantial increase in apoptotic cells in MFM223 ( 2.3 % vs 11.4 % respectively , p < 0.001 ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(56, 0), 'end':(56, 1), 'text':'To confirm'}, {'start':(56, 2), 'end':(56, 9), 'text':'that these observations represented ligand independent signalling ,'}]}, {'start':(56, 10), 'end':(56, 17), 'text':'we grew MFM223 in serum free medium .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(57, 0), 'end':(57, 10), 'text':'In the absence of serum MFM223 proliferated at a similar rate'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(57, 11), 'end':(57, 13), 'text':'compared to cells'}, {'start':(57, 14), 'end':(57, 19), 'text':'grown in 10 % serum .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(58, 0), 'end':(58, 12), 'text':'In the absence of serum MFM223 were dependent on FGFR for proliferation ,'}, {'start':(58, 13), 'end':(58, 23), 'text':'and underwent apoptosis in the presence of PD173074 ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 0), 'end':(59, 9), 'text':'FGFR2 amplified cell lines also have PI3 kinase pathway aberrations'}, {'label':'contrast', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(60, 0), 'end':(60, 1), 'text':'We noted'}, {'start':(60, 2), 'end':(60, 9), 'text':'that AKT was highly phosphorylated in MFM223 ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 10), 'end':(60, 17), 'text':'but that this was substantially decreased in PD173074'}, {'start':(60, 18), 'end':(60, 20), 'text':'treated cells .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'enablement', 'direction':'RightToLeft', 'children':[{'start':(61, 0), 'end':(61, 10), 'text':'To investigate whether this reflected an activating mutation in PIK3CA ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(61, 11), 'end':(61, 19), 'text':'we sequenced the helical and kinase domains of PIK3CA'}, {'start':(61, 20), 'end':(61, 31), 'text':'and identified a classical H1047R kinase mutation in MFM223 ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(62, 0), 'end':(62, 10), 'text':'The H1047R mutation has been described to active PI3 kinase function'}, {'start':(62, 11), 'end':(62, 19), 'text':'and transforms human mammary epithelial cells ( ) .'}]}, {'start':(63, 0), 'end':(63, 13), 'text':'We therefore examined the effect of dual targeting of PI3 kinase and FGFR .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(64, 0), 'end':(64, 18), 'text':'Treatment of MFM223 with the dual PI3 kinase and mTOR inhibitor BEZ235 ( ) abolished AKT phosphorylation ( )'}, {'start':(64, 19), 'end':(64, 27), 'text':'and substantially increased the subG1 fraction ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(65, 0), 'end':(65, 20), 'text':'Treatment with combination of BEZ235 and PD173074 increased the subG1 fraction to a greater extent than either drug given individually .'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(66, 0), 'end':(66, 10), 'text':'Similarly , dual treatment with both inhibitors had an additive effect'}, {'start':(66, 11), 'end':(66, 25), 'text':'as assessed by combination index ( CI ) assay ( , CI 1.02 ) .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(67, 0), 'end':(67, 4), 'text':'SUM52 had wild-type PIK3CA ,'}, {'label':'joint', 'direction':'None', 'children':[{'start':(67, 5), 'end':(67, 13), 'text':'but did not express PTEN protein ( ) ,'}, {'start':(67, 14), 'end':(67, 32), 'text':'and a similar additive CI was observed in SUM52 cells between PD173074 and BEZ235 ( CI 0.985 ) .'}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(68, 0), 'end':(68, 2), 'text':'These data suggests'}, {'start':(68, 3), 'end':(68, 19), 'text':'that dual targeting of FGFR2 and PIK3CA may be of benefit in cancers with FGFR2 amplification .'}]}]}]}]}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(69, 0), 'end':(69, 2), 'text':'Taken together ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 3), 'end':(69, 8), 'text':'our data provide strong circumstantial evidence'}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 9), 'end':(69, 20), 'text':'that FGFR2 may be a therapeutic target for a subset of TNBC'}, {'start':(69, 21), 'end':(69, 25), 'text':'harbouring FGFR2 gene amplification ,'}]}, {'start':(69, 26), 'end':(69, 38), 'text':'and that our method of integrated analysis of transcriptomic and genomic data ,'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(69, 39), 'end':(69, 41), 'text':'focused on genes'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(69, 42), 'end':(69, 44), 'text':'that are over-expressed'}, {'start':(69, 45), 'end':(69, 47), 'text':'when amplified ,'}]}]}]}, {'start':(69, 48), 'end':(69, 52), 'text':'identifies potential treatment targets .'}]}]}]}]}]}]}]}
199	200	{'start':(0, 0), 'end':(0, 1), 'text':'Supplementary Figures'}
196	197	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 9'}
203	204	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 5'}
197	198	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 10'}
193	194	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 1'}
204	205	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 6'}
198	199	{'start':(0, 0), 'end':(0, 4), 'text':'Supplementary Figure Legends , Methods'}
162	192	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(0, 0), 'end':(0, 0), 'text':'Discussion'}, {'label':'joint', 'direction':'None', 'children':[{'start':(1, 0), 'end':(1, 3), 'text':'TNBCs are genetically unstable'}, {'start':(1, 4), 'end':(1, 12), 'text':'and often harbour complex patterns of genetic aberrations .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(2, 0), 'end':(2, 18), 'text':'Using high resolution array CGH and gene expression platforms , tumours with > 70 % of neoplastic cells ,'}, {'start':(2, 19), 'end':(2, 28), 'text':'and only invasive ductal cancers of no special type ,'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(2, 29), 'end':(2, 31), 'text':'we have demonstrated'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(2, 32), 'end':(2, 40), 'text':'that a substantial proportion of genes have expression levels'}, {'start':(2, 41), 'end':(2, 50), 'text':'that significantly correlate with copy number in TN cancers .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 4), 'text':'Functional annotation of these genes'}, {'start':(3, 5), 'end':(3, 6), 'text':'using IPA'}]}, {'start':(3, 7), 'end':(3, 7), 'text':'revealed'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(3, 8), 'end':(3, 16), 'text':'that the canonical pathways of several tyrosine kinase receptors'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 17), 'end':(3, 27), 'text':'involved in tumourigenesis and cancer progression were enriched for the genes'}, {'start':(3, 28), 'end':(3, 37), 'text':'upregulated by copy number gain were enriched ( ) .'}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'start':(4, 0), 'end':(4, 12), 'text':'Interestingly , copy number gains of the tyrosine kinase receptors were rare ;'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(4, 13), 'end':(4, 23), 'text':'instead , upregulation of signal transduction kinases downstream of the receptors'}, {'start':(4, 24), 'end':(4, 48), 'text':'( e.g. RAF1 , PTK2 , PIK3C2G , CSNK1D , MAPK9 ) and adaptor proteins ( e.g. , GRB2 , GAB1 ) was observed .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(5, 0), 'end':(5, 2), 'text':'It is possible'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(5, 3), 'end':(5, 21), 'text':'that these recurrent copy number gains , of multiple components of the canonical pathways of tyrosine kinase receptors ,'}, {'start':(5, 22), 'end':(5, 36), 'text':'could create a permissive context for activation of these pathways in TN breast cancers .'}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(6, 0), 'end':(6, 4), 'text':'In addition this observation suggests'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(6, 5), 'end':(6, 7), 'text':'that in TNBCs'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 8), 'end':(6, 18), 'text':'it may be possible to identify commonly activated signal transduction pathways'}, {'start':(6, 19), 'end':(6, 27), 'text':'that could be targeted effectively for TNBC therapy .'}]}]}]}]}]}, {'start':(7, 0), 'end':(7, 48), 'text':'The majority of TNBCs showed losses on 1p , 2q , 3p , 4p , 5q , 8p 9q , 16q , 17p , 19p , and 23p ; and gains on 1p , 3q , 6p , 9p , 7q , 8p , 10p , and 12p .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'explanation', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 26), 'text':'Only 11 % of the tumours in our cohort showed concurrent 1q gain and 16q loss , the typical changes of low-grade ER positive breast cancers ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 27), 'end':(8, 32), 'text':'in agreement with our previous results'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(8, 33), 'end':(8, 33), 'text':'suggesting'}, {'start':(8, 34), 'end':(8, 50), 'text':'that progression from grade I to grade III is an uncommon phenomenon in TNBCs ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 3), 'text':'It should be noted'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(9, 4), 'end':(9, 8), 'text':'that many of the regions'}, {'start':(9, 9), 'end':(9, 48), 'text':'that were affected by genetic aberrations in TNBCs such as gain of 1q , 3q , 7q , 8q , and 10p and loss of 4p , 5q , 17p , and 8p , have also been found in tumours'}]}, {'start':(9, 49), 'end':(9, 56), 'text':'arising in BRCA1 mutation carriers ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 9), 'text':'These results highlight the similarities between sporadic TNBCs and tumours'}, {'label':'joint', 'direction':'None', 'children':[{'start':(10, 10), 'end':(10, 14), 'text':'arising in BRCA1 mutation carriers'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 15), 'end':(10, 21), 'text':'and provide yet another line of evidence'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(10, 22), 'end':(10, 23), 'text':'to suggest'}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(10, 24), 'end':(10, 29), 'text':'that , as a group ,'}, {'start':(10, 30), 'end':(10, 37), 'text':'TNBCs phenocopy familial BRCA1 tumours ( ) .'}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 5), 'text':'Similar to the HER2 amplicon ,'}, {'start':(11, 6), 'end':(11, 14), 'text':'whose smallest regions of amplification encompasses 13 genes ,'}]}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(11, 15), 'end':(11, 24), 'text':'of which only 7 are expressed at significantly higher levels'}, {'start':(11, 25), 'end':(11, 27), 'text':'when amplified ,'}]}]}, {'start':(11, 28), 'end':(11, 30), 'text':'our analysis demonstrated'}]}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(11, 31), 'end':(11, 35), 'text':'that only a few genes'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 36), 'end':(11, 38), 'text':'mapping to regions'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(11, 39), 'end':(11, 47), 'text':'recurrently amplified in TN breast cancers were consistently overexpressed'}, {'start':(11, 48), 'end':(11, 50), 'text':'when amplified .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 2), 'text':'Importantly , genes'}, {'start':(12, 3), 'end':(12, 6), 'text':'identified in this study'}]}, {'start':(12, 7), 'end':(12, 8), 'text':'as overexpressed'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 9), 'end':(12, 16), 'text':'when amplified may constitute potential therapeutic targets ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(12, 17), 'end':(12, 44), 'text':'including FGFR2 ( 10q26 ) , mitotic spindle checkpoint protein BUB3 ( 10q26 ) , RAS oncogene family member RAB20 ( 13q34 ) , Notch family member NOTCH3'}, {'start':(12, 45), 'end':(12, 60), 'text':'( 19p13 ) and the protein kinase C super family member PKN1 ( 19p13 ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 7), 'text':'Our data adds to the body of evidence'}, {'start':(13, 8), 'end':(13, 16), 'text':'linking aberrant FGF signaling to breast cancer pathogenesis .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 18), 'text':'Interestingly , a SNP in FGFR2 intron 2 is a common low risk predisposition gene for breast cancer ,'}, {'start':(14, 19), 'end':(14, 27), 'text':'that predisposes selectively for ER positive breast cancer .'}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(15, 0), 'end':(15, 4), 'text':'In contrast our data suggest'}, {'start':(15, 5), 'end':(15, 15), 'text':'that amplification of FGFR2 is found in ER negative TNBCs .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 8), 'text':'Most TNBCs exhibit high levels of genomic instability ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 9), 'end':(16, 17), 'text':'which potentially reflects an underlying defect in the processes'}, {'start':(16, 18), 'end':(16, 22), 'text':'that maintain genome stability ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 23), 'end':(16, 30), 'text':'and this defect could theoretically provide a mechanism'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 31), 'end':(16, 38), 'text':'through which some TNBCs acquire FGFR2 amplfication ,'}, {'start':(16, 39), 'end':(16, 49), 'text':'coupled with the survival advantage conferred by activated FGFR2 signalling .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(17, 0), 'end':(17, 8), 'text':'Activating mutations in FGFR2 are found in endometrial cancer'}, {'start':(17, 9), 'end':(17, 11), 'text':'( ) ,'}]}, {'start':(17, 12), 'end':(17, 20), 'text':'but are rare in breast cancer ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(18, 0), 'end':(18, 1), 'text':'We confirmed'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 2), 'end':(18, 4), 'text':'that a mechanism'}, {'start':(18, 5), 'end':(18, 26), 'text':'underlying oncogene addiction in cell lines with FGFR2 gene amplification is activation of PI3K-AKT signalling , and resulting inhibition of apoptosis .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 0), 'end':(19, 3), 'text':'Signalling in cell lines'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 4), 'end':(19, 16), 'text':'harbouring FGFR2 amplification appears to be ligand independent , with both cell lines'}, {'start':(19, 17), 'end':(19, 25), 'text':'activating AKT in an FGFR kinase dependent manner .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 26), 'text':'Interestingly , in MFM223 , AKT phosphorylation was predominantly under control of upstream FGFR signalling despite the presence of an activating PI3KCA kinase mutation ( ) ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(20, 27), 'end':(20, 27), 'text':'suggesting'}, {'start':(20, 28), 'end':(20, 41), 'text':'that in this cell line PI3KCA kinase domain mutation predominantly amplified upstream signal .'}]}]}, {'label':'contrast', 'direction':'LeftToRight', 'children':[{'start':(21, 0), 'end':(21, 7), 'text':'Likewise SUM52 remained sensitive to FGFR inhibition ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 8), 'end':(21, 11), 'text':'despite lacking PTEN expression'}, {'start':(21, 12), 'end':(21, 14), 'text':'( ) ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(21, 15), 'end':(21, 18), 'text':'concurring with previous results'}, {'start':(21, 19), 'end':(21, 29), 'text':'found in FGFR2 mutant endometrial cancer cell lines ( ) .'}]}]}]}]}]}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(22, 0), 'end':(22, 1), 'text':'We note'}, {'start':(22, 2), 'end':(22, 14), 'text':'that HCC1143 have been shown to harbour an FGFR2 mutation ( ) .'}]}]}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 19), 'text':'HCC1143 show no evidence of FGFR dependent signalling ( ) , nor dependence on FGFR for proliferation ( ) ,'}, {'start':(23, 20), 'end':(23, 22), 'text':'suggesting the mutation'}]}, {'start':(23, 23), 'end':(23, 23), 'text':'identified'}]}, {'start':(23, 24), 'end':(23, 32), 'text':'( R203C ) does not active the receptor .'}]}]}]}]}]}, {'label':'contrast', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 13), 'text':'Here , we have identified a higher number of recurrent amplifications in TN cancers'}, {'start':(24, 14), 'end':(24, 17), 'text':'than previously reported ,'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 18), 'end':(24, 32), 'text':'possibly due to the use of samples with > 70 % of tumour cells ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 33), 'end':(24, 36), 'text':'which reduces the bias'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(24, 37), 'end':(24, 45), 'text':'introduced by the contamination with diploid non neoplastic cells'}, {'start':(24, 46), 'end':(24, 54), 'text':'( i.e. stromal cells and inflammatory infiltrate ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(25, 0), 'end':(25, 7), 'text':'In fact , 76.8 % of the tumours'}, {'start':(25, 8), 'end':(25, 22), 'text':'analysed in this study harboured at least one focal ( < 10Mb ) amplification .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(26, 0), 'end':(26, 14), 'text':'However , the majority of these amplifications were shown to occur at low frequency ,'}, {'label':'attribution', 'direction':'RightToLeft', 'children':[{'start':(26, 15), 'end':(26, 15), 'text':'confirming'}, {'start':(26, 16), 'end':(26, 25), 'text':'that at the genomic level TNBCs are genomically heterogeneous .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 3), 'text':'To develop therapeutic strategies'}, {'start':(27, 4), 'end':(27, 16), 'text':'directed at drivers of the recurrent amplicons in TNBC will be challenging ,'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(27, 17), 'end':(27, 24), 'text':'requiring comprehensive molecular pathology analyses of primary tumours'}, {'start':(27, 25), 'end':(27, 35), 'text':'to select the appropriate targeted therapy for the individual tumours .'}]}]}]}, {'label':'condition', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 10), 'text':'A novel approach to clinical trial design would also be required'}, {'start':(28, 11), 'end':(28, 19), 'text':'if rare oncogenic targets are to be validated .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 15), 'text':'An alternative approach to the therapy of TNBCs would be to identify shared signal transduction pathways'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(29, 16), 'end':(29, 22), 'text':'that could be targeted for tumour treatment'}, {'start':(29, 23), 'end':(29, 28), 'text':'without targeting the oncogene directly .'}]}]}]}]}]}]}]}]}
27	92	{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(0, 0), 'end':(0, 2), 'text':'Material and Methods'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(1, 0), 'end':(1, 1), 'text':'Tumour samples'}, {'start':(2, 0), 'end':(2, 18), 'text':'Fifty-six fresh-frozen samples of TNBCs were obtained after approval by local Ethic Committees from the authors \' institutions .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(3, 0), 'end':(3, 16), 'text':'Triple negative tumours were selected according to their lack of expression to ER , PR and HER2'}, {'start':(3, 17), 'end':(3, 23), 'text':'as defined by immunohistochemistry ( ) .'}]}, {'start':(4, 0), 'end':(4, 11), 'text':'All tumours were morphologically invasive ductal cancers of no special type .'}]}]}, {'start':(5, 0), 'end':(5, 16), 'text':'ER , PR and HER2 antibodies , antigen retrieval systems and scoring methods are summarised in .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(6, 0), 'end':(6, 10), 'text':'One representative section of each tumour was stained with haematoxiylin-eosin .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'condition', 'direction':'LeftToRight', 'children':[{'start':(7, 0), 'end':(7, 24), 'text':'Samples were either microdissected with a sterile needle under a stereomicroscope ( ) , or samples from Kreike et al. ( ) were only included'}, {'start':(7, 25), 'end':(7, 37), 'text':'if there were > 70 % of neoplastic cells in the section .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(8, 0), 'end':(8, 5), 'text':'A complete description of the cohort'}, {'start':(8, 6), 'end':(8, 11), 'text':'analysed here is described in .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(9, 0), 'end':(9, 8), 'text':'Out of the samples included in this study ,'}, {'start':(9, 9), 'end':(9, 38), 'text':'the aCGH profiles of 23 cases were reported in Natrajan et al. ( ) and the expression profiles of 24 cases were reported in Kreike et al. ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(10, 0), 'end':(10, 20), 'text':'No statistically significant differences were observed in terms of patient age , tumour size , histological grade , prevalence of basal'}, {'start':(10, 21), 'end':(10, 41), 'text':'like phenotype and outcome between the 24 cases included in this study , and the remaining TNBCs from ; ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(11, 0), 'end':(11, 3), 'text':'RNA and DNA extraction'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(12, 0), 'end':(12, 4), 'text':'DNA and RNA were extracted'}, {'start':(12, 5), 'end':(12, 8), 'text':'as previously described .'}]}]}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(13, 0), 'end':(13, 8), 'text':'DNA concentration was measured with Picogreen ( R )'}, {'start':(13, 9), 'end':(13, 14), 'text':'( Invitrogen , Paisley UK )'}]}, {'start':(13, 15), 'end':(13, 23), 'text':'according to the manufacturer \'s instructions ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(14, 0), 'end':(14, 4), 'text':'Microarray Based Comparative Genomic Hybridisation'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(15, 0), 'end':(15, 7), 'text':'The 32K BAC re-array collection ( CHORI )'}, {'start':(15, 8), 'end':(15, 27), 'text':'tiling path aCGH platform was constructed at the Breakthrough Breast Cancer Research Centre , as described previously ( ) .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(16, 0), 'end':(16, 24), 'text':'This type of BAC array platform has been shown to be as robust as and to have comparable resolution with high density oligonucleotide arrays .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(17, 0), 'end':(17, 15), 'text':'DNA labelling , array hybridisations and image acquisition were performed as previously described ( ) .'}, {'label':'joint', 'direction':'None', 'children':[{'start':(18, 0), 'end':(18, 3), 'text':'aCGH data were pre-processed'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(18, 4), 'end':(18, 10), 'text':'and analysed using an in-house R script'}, {'start':(18, 11), 'end':(18, 18), 'text':'( BACE.R ) in R version 2.9.0 ,'}]}, {'start':(18, 19), 'end':(18, 22), 'text':'as previously described .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'RightToLeft', 'children':[{'start':(19, 0), 'end':(19, 14), 'text':'After filtering polymorphic BACs , a final dataset of 31544 clones with unambiguous mapping information'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(19, 15), 'end':(19, 27), 'text':'according to the August 2009 build ( hg19 ) of the human genome'}, {'start':(19, 28), 'end':(19, 42), 'text':'( http://www.ensembl.org ) was smoothed using the circular binary segmentation ( cbs ) algorithm .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'attribution', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(20, 0), 'end':(20, 7), 'text':'A categorical analysis was applied to the BACs'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(20, 8), 'end':(20, 13), 'text':'after classifying them as representing amplification'}, {'start':(20, 14), 'end':(20, 18), 'text':'( > 0.45 ) ,'}]}]}, {'start':(20, 19), 'end':(20, 46), 'text':'gain ( > 0.08 and < = 0.045 ) , loss ( < -0.08 ) , or no-change according to their cbs smoothed Log 2 ratio values .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(21, 0), 'end':(21, 3), 'text':'Threshold values were determined'}, {'start':(21, 4), 'end':(21, 11), 'text':'and validated as previously described ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(22, 0), 'end':(22, 21), 'text':'Tumours were classified according to their pattern of genomic alterations into \' simplex \' , \' firestorm \' or \' sawtooth \''}, {'start':(22, 22), 'end':(22, 25), 'text':'as previously described .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(23, 0), 'end':(23, 2), 'text':'Gene expression analysis'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(24, 0), 'end':(24, 11), 'text':'RNA labelling , hybridisation , slide scanning and data normalisation were performed'}, {'start':(24, 12), 'end':(24, 15), 'text':'as previously described .'}]}]}]}]}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(25, 0), 'end':(25, 3), 'text':'Fluorescent intensities were normalised'}, {'start':(25, 4), 'end':(25, 10), 'text':'and corrected for biases ( ) ,'}]}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(25, 11), 'end':(25, 18), 'text':'and weighted averages and confidence levels were computed'}, {'start':(25, 19), 'end':(25, 27), 'text':'according to the Rosetta Error Model ( ) .'}]}]}]}, {'start':(26, 0), 'end':(26, 9), 'text':'All the expression data can be retrieved from http://www.ebi.ac.uk/microarrayas/ae/browse.html?keywords=E-NCMF-2&species=&array=&exptype=&pagesize=25&sortby=releasedate&sortorder=descending .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 0), 'end':(27, 11), 'text':'Of the TNBCs analysed , 94.2 % were of basal like phenotype'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(27, 12), 'end':(27, 14), 'text':'using the criteria'}, {'start':(27, 15), 'end':(27, 20), 'text':'described by Hu et al. .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(28, 0), 'end':(28, 2), 'text':'Identification of genes'}, {'start':(28, 3), 'end':(28, 9), 'text':'whose expression correlates with copy number changes'}]}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 0), 'end':(29, 2), 'text':'To identify genes'}, {'start':(29, 3), 'end':(29, 11), 'text':'whose expression levels correlate with copy number changes ,'}]}, {'label':'enablement', 'direction':'LeftToRight', 'children':[{'start':(29, 12), 'end':(29, 21), 'text':'cbs smoothed Log 2 ratios from aCGH data were used'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 22), 'end':(29, 37), 'text':'to assign the aCGH states for each of the 24,650 genes in the gene expression dataset'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(29, 38), 'end':(29, 44), 'text':'using the median values for all BACs'}, {'start':(29, 45), 'end':(29, 54), 'text':'which overlap with the genomic position of each gene .'}]}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(30, 0), 'end':(30, 13), 'text':'This resulted in a 1:1 matrix of expression ratios and aCGH cbs values ,'}, {'start':(30, 14), 'end':(30, 21), 'text':'which were used for downstream statistical analysis .'}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(31, 0), 'end':(31, 15), 'text':'Pearson \'s correlations were performed between gene expression array Log 2 ratios and cbs smoothed ratios'}, {'start':(31, 16), 'end':(31, 23), 'text':'derived from aCGH analysis for each gene .'}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(32, 0), 'end':(32, 9), 'text':'The p values for each test were adjusted with Benjamini'}, {'start':(32, 10), 'end':(32, 17), 'text':'and Hochberg multiple p-value adjustment ( ) .'}]}]}]}, {'start':(33, 0), 'end':(33, 8), 'text':'Adjusted p values < 0.05 were considered significant .'}]}]}, {'label':'enablement', 'direction':'RightToLeft', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 0), 'end':(34, 2), 'text':'To define genes'}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(34, 3), 'end':(34, 5), 'text':'that were upregulated'}, {'start':(34, 6), 'end':(34, 8), 'text':'when gained ,'}]}]}, {'label':'background', 'direction':'LeftToRight', 'children':[{'start':(34, 9), 'end':(34, 13), 'text':'downregulated when lost or overexpressed'}, {'start':(34, 14), 'end':(34, 16), 'text':'when amplified ,'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 17), 'end':(34, 22), 'text':'we performed a multi-Mann-Whitney U test'}, {'label':'same-unit', 'direction':'None', 'children':[{'start':(34, 23), 'end':(34, 43), 'text':'using categorical aCGH states ( i.e. gain vs no gain , loss vs no loss or amplification vs no amplification )'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(34, 44), 'end':(34, 56), 'text':'as the grouping variable and the expression of genes as the dependent variable'}, {'start':(34, 57), 'end':(34, 60), 'text':'as previously described .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(35, 0), 'end':(35, 4), 'text':'P-values were adjusted using Benjamini'}, {'start':(35, 5), 'end':(35, 13), 'text':'and Hochberg multiple comparison p-value adjustment ( ) .'}]}, {'start':(36, 0), 'end':(36, 8), 'text':'Adjusted p values < 0.05 were considered significant .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'start':(37, 0), 'end':(37, 5), 'text':'For regions of recurrent amplification ,'}, {'label':'manner-means', 'direction':'LeftToRight', 'children':[{'start':(37, 6), 'end':(37, 9), 'text':'matched heatmaps were created'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(37, 10), 'end':(37, 22), 'text':'by retrieving gene expression values and corresponding median-overlay aCGH states for each gene'}, {'start':(37, 23), 'end':(37, 26), 'text':'as previously described .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'joint', 'direction':'None', 'children':[{'start':(38, 0), 'end':(38, 6), 'text':'Genes were ordered according to chromosomal location'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(38, 7), 'end':(38, 12), 'text':'and cases were separated into those'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(38, 13), 'end':(38, 20), 'text':'that harbour amplifications in the region and those'}, {'start':(38, 21), 'end':(38, 24), 'text':'which do not .'}]}]}]}, {'label':'joint', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(39, 0), 'end':(39, 6), 'text':'Within these groups the samples were ordered'}, {'start':(39, 7), 'end':(39, 17), 'text':'based upon the sum of expression values within the region .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(40, 0), 'end':(40, 2), 'text':'Ingenuity pathway analysis'}, {'start':(41, 0), 'end':(41, 17), 'text':'Ingenuity pathway analysis ( IPA ) program ( http://www.ingenuity.com ) was used as previously described ( ) .'}]}]}, {'label':'joint', 'direction':'None', 'children':[{'start':(42, 0), 'end':(42, 11), 'text':'HUGO gene identifiers were mapped to networks available in the Ingenuity database'}, {'start':(42, 12), 'end':(42, 16), 'text':'and ranked by score .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(43, 0), 'end':(43, 10), 'text':'The score indicates the likelihood of the genes in a network'}, {'start':(43, 11), 'end':(43, 18), 'text':'being found together due to random chance .'}]}, {'label':'background', 'direction':'RightToLeft', 'children':[{'start':(44, 0), 'end':(44, 6), 'text':'Using a 99 % confidence level ,'}, {'start':(44, 7), 'end':(44, 15), 'text':'scores of > = 3 are considered significant .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(45, 0), 'end':(45, 5), 'text':'Cell lines , materials and antibodies'}, {'label':'joint', 'direction':'None', 'children':[{'start':(46, 0), 'end':(46, 8), 'text':'Cell lines were obtained from ATCC or DMSZ ,'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(46, 9), 'end':(46, 28), 'text':'and maintained in DMEM or RPMI with 10 % FBS ( PAA gold ) and 2mM L-glutamine ( Sigma )'}, {'start':(46, 29), 'end':(46, 35), 'text':'( details available on request ) .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(47, 0), 'end':(47, 12), 'text':'S68 was a kind gift of Veronique Catros , Rennes , France .'}, {'start':(48, 0), 'end':(48, 15), 'text':'PD173074 was obtained from Sigma , BEZ235 from Axon Medchemicals , and U0126 from Calbiochem .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(49, 0), 'end':(49, 5), 'text':'siRNA were purchased from Dharmacon :'}, {'start':(49, 6), 'end':(49, 27), 'text':'FGFR2 siGenome SMARTpool ( siFGFR2 , M-003132-04 ) and siGENOME Non Targeting siRNA Pool # 1 ( siCON , D-001206-13 ) .'}]}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(50, 0), 'end':(50, 3), 'text':'Antibodies used were FGFR2'}, {'start':(50, 4), 'end':(50, 29), 'text':'( sc-122 , Santa-Cruz ) , phospho-FRS2-Tyr196 ( 3864 , Cell Signaling ) , phospho-AKT-Ser473 ( 4058 , Cell Signaling ) , phospho-ERK1 / 2-Thr202 /'}]}, {'start':(50, 30), 'end':(50, 45), 'text':'Tyr204 ( 4370 , Cell Signaling ) , and beta-Actin ( sc-1616 , Santa-Cruz ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(51, 0), 'end':(51, 9), 'text':'Cell line drug sensitivity , siRNA transfection and FACS analysis'}, {'label':'attribution', 'direction':'LeftToRight', 'children':[{'start':(52, 0), 'end':(52, 36), 'text':'Cell lines were transfected with siCON or siFGFR2 in 96 well plates with Lipofectamine RNAiMax ( Invitrogen ) , Lipofectamine 2000 ( Invitrogen ) , Dharmafect 3 ( Thermo Scientific ) , or Oligofectamine ( Invitrogen )'}, {'start':(52, 37), 'end':(52, 41), 'text':'according to manufacturers instructions .'}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(53, 0), 'end':(53, 29), 'text':'Transfection of all cell lines was confirmed with positive control PLK1 siRNA ( loss of survival < 25 % that of siCON transfection in all cell lines , ) .'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(54, 0), 'end':(54, 21), 'text':'Survival was assessed with Cell Titre-Glo ( R ) cell viability assay ( Promega ) after five population doublings or 7 days'}, {'start':(54, 22), 'end':(54, 26), 'text':'which ever was shorter .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(55, 0), 'end':(55, 17), 'text':'For sensitivity to PD173074 , cell lines were plated in 96 well plates , the following day media'}, {'start':(55, 18), 'end':(55, 26), 'text':'supplemented with PD173074 at increasing concentrations , and survival'}]}, {'start':(55, 27), 'end':(55, 30), 'text':'assessed with Cell Titre-Glo'}]}, {'start':(55, 31), 'end':(55, 38), 'text':'( R ) after 96 hours exposure .'}]}, {'start':(56, 0), 'end':(56, 12), 'text':'Survival curves and estimated SF50 were calculated with GraphPad prism V5 .0 .'}]}]}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(57, 0), 'end':(57, 29), 'text':'For Combination Index ( CI ) cells were treated in 96 well plate for 96 hrs with two fold dilutions of PD173074 , BEZ235 , or combination , and CI'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(57, 30), 'end':(57, 37), 'text':'calculated using non mutually exclusive median effect model'}, {'start':(57, 38), 'end':(57, 43), 'text':'as described previously ( ) .'}]}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'background', 'direction':'LeftToRight', 'children':[{'start':(58, 0), 'end':(58, 3), 'text':'FACS analysis was performed'}, {'start':(58, 4), 'end':(58, 9), 'text':'as described previously ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(59, 0), 'end':(59, 1), 'text':'Western blotting'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(60, 0), 'end':(60, 2), 'text':'Indicated cell lines'}, {'label':'joint', 'direction':'None', 'children':[{'start':(60, 3), 'end':(60, 8), 'text':'where grown on 10cm plates ,'}, {'start':(60, 9), 'end':(60, 21), 'text':'and grown for 24 hrs in serum free medium or normal medium .'}]}]}]}]}]}, {'start':(61, 0), 'end':(61, 13), 'text':'Where indicated plates were treated with drug for 1 hour prior to lysis .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(62, 0), 'end':(62, 10), 'text':'Western blots were carried out with precast TA or Bis-Tris gels'}, {'start':(62, 11), 'end':(62, 13), 'text':'( Invitrogen )'}]}, {'start':(62, 14), 'end':(62, 19), 'text':'as described previously ( ) .'}]}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(63, 0), 'end':(63, 5), 'text':'Fluorescence in situ hybridisation for FGFR2'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 0), 'end':(64, 13), 'text':'FGFR2 gene copy number status was assessed in breast cancer cell lines with in-house'}, {'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 14), 'end':(64, 16), 'text':'generated BAC probes'}, {'label':'same-unit', 'direction':'None', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'label':'elaboration', 'direction':'LeftToRight', 'children':[{'start':(64, 17), 'end':(64, 19), 'text':'comprising two BACs'}, {'start':(64, 20), 'end':(64, 25), 'text':'( RP11-300A10 and RP11-753P11 ) ,'}]}, {'start':(64, 26), 'end':(64, 35), 'text':'which map to specifically to the FGFR2 gene locus ,'}]}, {'start':(64, 36), 'end':(64, 41), 'text':'as previously described ( ) .'}]}]}]}]}]}]}]}]}
194	195	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 7'}
201	202	{'start':(0, 0), 'end':(0, 2), 'text':'Supplementary Table 3'}
